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**Abstract**

Cerebrospinal fluid (CSF) is derived from the brain tissue as well as the choroid plexus, and is in continuity with the brain interstitial fluid. Molecules released from brain cells can directly diffuse into the CSF. There are established CSF biomarkers for brain disorders. For example, tau, phosphorylated tau, and Abeta42 levels in CSF are useful biomarkers in the diagnosis of Alzheimer's disease, although levels of these molecules in peripheral blood are not of clinical use. To explore such biomarkers in psychiatric disorders, we have been collecting CSF samples from patients with schizophrenia, major depressive disorder (MDD), bipolar disorder, and normal controls. We have thus far collected more than 700 samples for research. To develop a biomarker for the psychiatric disorders, we have performed both targeted and untargeted approaches on the CSF samples. For the untargeted approach, we conducted an aptamer-based proteomics analyses which measured 1129 proteins with high accuracy in a selected sample of 30 patients with schizophrenia, 30 with MDD, 16 with bipolar disorder and 30 controls, matched for age and sex. One of the top candidate proteins for MDD in the analyses was fibrinogen. An approximately one fourth of the MDD patients had an excessively high level of CSF fibrinogen. By using fibrinogen ELISA, we obtained similar results in an independent sample set consist of 36 MDD and 30 controls. We then confirmed the high fibrinogen patients in a total of 384 subjects. We also found that fibrinogen levels reduced after electroconvulsive therapy. When MRI brain imaging data were combined, the diffusion tensor imaging analysis revealed white matter tract abnormalities in the patients with a high fibrinogen level but not in the patients with a normal fibrinogen level or in the control subjects. Our results point to a subgroup of MDD represented by increased CSF fibrinogen and white matter tract abnormalities. Omics approaches on CSF samples may be a promising strategy to elucidate biomarkers and brain pathophysiology of psychiatric diseases. The omics database we are creating would also be useful for a number of neurological diseases.

**References**

Hattori et al., Increased cerebrospinal fluid fibrinogen in major depressive disorder, Sci Rep. 5:11412, 2015

Ogawa et al., Reduced cerebrospinal fluid ethanolamine concentration in major depressive disorder. Sci Rep. 5:7796, 2015
